Home Science AbbVie would gain an experimental eczema drug by buying...
Science

AbbVie would gain an experimental eczema drug by buying biotech: report

AbbVie would gain an experimental eczema drug by buying biotech: report
Key Points

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
AbbVie (PERSON) Financial Times (ORG)
Originally published by MarketWatch Read original →